The Food and Drug Administration (FDA) appears closer than ever to approving psychedelic drugs like psilocybin and MDMA for medical use. But as political momentum builds in Washington and in the states, the evidence supporting these drugs deserves more scrutiny, not less.
Earlier this month, the Food and Drug Administration released its first finalized guidance on psychedelic drug development, explaining how these drugs should be studied for potential medical approval. The document marks a turning point. After decades of resistance, the FDA is signaling that psilocybin and MDMA are now on a path toward approval.
This seismic shift in psychedelics acceptance isn’t just about approving a new medicine. It’s about whether the federal government is laying the foundation for a multibillion-dollar commercial psychedelic industry before it has answered the fundamental scientific questions that should come first.
President Trump made psychedelics a priority by signing an executive order in April aimed at accelerating their development. The momentum has extended beyond Washington. Podcast host Joe Rogan later said he persuaded the president with a single text message supporting psychedelic therapies. Within days, the FDA awarded National Priority Vouchers to Compass Pathways, Transcend Therapeutics, and the Usona Institute, dramatically accelerating review timelines for their products. Health and Human Services Secretary Robert F. Kennedy Jr. has also publicly predicted psychedelic therapies could become available within a year.
These moves inspired bipartisan concern about giving certain companies an inside path to approval.
There is no cause for concern if psychedelic therapies pass the scientific muster required for approval. But the question now is whether the evidence has reached the threshold the FDA has historically required to make that determination. When the Oval Office is used to publicly encourage approvals, celebrate psychedelic therapies, and accelerate review timelines before those scientific questions have been answered, it’s fair to ask whether the FDA is being maneuvered to move faster than the evidence warrants.
The FDA is not supposed to be a political weathervane. Their job is to determine whether these drugs have actually met the rigorous scientific standards required of every new medicine.
Supporters often point to promising studies suggesting psychedelics can treat depression, PTSD, addiction, and other serious conditions. But many of those studies are remarkably small and suffer from methodological weaknesses and conflicts of interest. A 2024 review of nearly 300 psilocybin studies found that only 12 percent were randomized controlled trials, with a median sample size of just 22 participants. Flimsy evidence like that is no basis for promising veterans a “miracle cure,” as U.S. Rep. Lou Correa (D-CA) recently said.
The FDA’s own guidance reinforces that point. The agency recommends following patients for at least twelve months because long-term effects remain uncertain. It also suggests abuse studies may not be scientifically necessary for certain psychedelics because their subjective effects are already “well characterized.”
Widespread abuse means there should be greater scrutiny, not less.
The public has already seen what those “well-characterized” effects can look like. Alaska Airlines pilot Joseph Emerson attempted to shut down the engines of a commercial flight after experiencing lingering effects from a psilocybin experience he had days prior. Whether or not this story means anything about the bigger picture isn’t the point. It illustrates why rigorous safety review cannot become an afterthought simply because political enthusiasm and massive investment are accelerating.
The FDA’s own guidance makes one thing clear: significant questions about long-term outcomes and abuse potential remain unanswered. Those aren’t minor details to look into after administering these high-powered drugs to vulnerable populations. They’re exactly the kinds of questions the agency exists to resolve before approving a new medicine. If the evidence ultimately supports approval, the FDA’s scientific review should make that case on its own. It should not need political momentum to carry it across the finish line. Until those questions are answered, the agency should resist pressure to move faster than science allows.
Science should decide the future of psychedelics – not politics.
